Juan F. Vázquez-Costa

Prof. Dr. Juan F. Vázquez-Costa

Hospital Universitari i Politècnic La Fe, Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Neurology
Verified
Journal Article
Open access
PDF file
LALaura Antolini
Laura Antolini
JDJacopo C. DiFrancesco
Jacopo C. DiFrancesco
MZMarialuisa Zedde
Marialuisa Zedde
GBGianpaolo Basso
Gianpaolo Basso
AAAndrea Arighi
Andrea Arighi
FPFabrizio Piazza
Fabrizio Piazza
Background and Objectives The goal of this work was to investigate the natural history and outcomes after treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like in cerebral amyloid angiopathy–related inflammation (CAA-ri). Methods This was a multicenter, hospital-based, longitudinal, prospective observational study of inpatients meeting CAA-ri diagnostic criteria recruited through the Inflammatory Cerebral Amyloid Angiopathy and Alzheimer9s Disease βiomarkers International Network from January 2013 to March 2017. A protocol for systematic data collection at first-ever presentation and at subsequent in-person visits, including T1-weighted, gradient recalled echo–T2*, fluid-suppressed T2-weighted (fluid-attenuated inversion recovery), and T1 postgadolinium contrast-enhanced images acquired on 1.5T MRI, was used at the 3-, 6-, 12-, and 24-month follow-up. Centralized reads of MRIs were performed by investigators blinded to clinical, therapeutic, and time-point information. Main outcomes were survival, clinical and radiologic recovery, intracerebral hemorrhage (ICH), and recurrence of CAA-ri. Results The study enrolled 113 participants (10.6% definite, 71.7% probable, and 17.7% possible CAA-ri). Their mean age was 72.9 years; 43.4% were female; 37.1% were APOEε4 carriers; 36.3% had a history of Alzheimer disease; and 33.6% had a history of ICH. A history of ICH and the occurrence of new ICH at follow-up were more common in patients with cortical superficial siderosis at baseline (52.6% vs 14.3%, p < 0.0001 and 19.3% vs 3.6%, p < 0.009, respectively). After the first-ever presentation of CAA-ri, 70.3% (95% confidence interval [CI] 61.6%–78.5%) and 84.1% (95% CI 76.2%–90.6%) clinically recovered within 3 and 12 months, followed by radiologic recovery in 45.1% (95% CI 36.4%–54.8%) and 77.4% (95% CI 67.7%–85.9%), respectively. After clinicoradiologic resolution of the first-ever episode, 38.3% (95% CI 22.9%–59.2%) had at least 1 recurrence within the following 24 months. Recurrence was more likely if IV high-dose corticosteroid pulse therapy was suddenly stopped compared to slow oral tapering off (hazard ratio 4.68, 95% CI 1.57–13.93; p = 0.006). Discussion These results from the largest longitudinal cohort registry of patients with CAA-ri support the transient and potentially relapsing inflammatory nature of the clinical-radiologic acute manifestations of the disease and the effectiveness of slow oral tapering off after IV corticosteroid pulse therapy in preventing recurrences. Our results highlight the importance of differential diagnosis for spontaneous ARIA-like events in β-amyloid–driven diseases, including treatment-related ARIA in patients with Alzheimer disease exposed to immunotherapy drugs.

29 October 2013 in Neurology
Verified
Journal Article
Closed access
PDF file
RSRafael Sivera
Rafael Sivera
TSTeresa Sevilla
Teresa Sevilla
JVJuan J Vilchez
Juan J Vilchez
DMDolores Martínez-Rubio
Dolores Martínez-Rubio
MCMaría José Chumillas
María José Chumillas
Carmen EspinósCarmen Espinós
Carmen Espinós
Objectives: To determine the genetic distribution and the phenotypic correlation of an extensive series of patients with Charcot-Marie-Tooth disease in a geographically well-defined Mediterranean area. Methods: A thorough genetic screening, including most of the known genes involved in this disease, was performed and analyzed in this longitudinal descriptive study. Clinical data were analyzed and compared among the genetic subgroups. Results: Molecular diagnosis was accomplished in 365 of 438 patients (83.3%), with a higher success rate in demyelinating forms of the disease. The CMT1A duplication (PMP22 gene) was the most frequent genetic diagnosis (50.4%), followed by mutations in the GJB1 gene (15.3%), and in the GDAP1 gene (11.5%). Mutations in 13 other genes were identified, but were much less frequent. Sixteen novel mutations were detected and characterized phenotypically. Conclusions: The relatively high frequency of GDAP1 mutations, coupled with the scarceness of MFN2 mutations (1.1%) and the high proportion of recessive inheritance (11.6%) in this series exemplify the particularity of the genetic distribution of Charcot-Marie-Tooth disease in this region.

28 December 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MFMarina Frasquet
Marina Frasquet
RRRicard Rojas-Garcia
Ricard Rojas-Garcia
HAHerminia Argente‐Escrig
Herminia Argente‐Escrig
Juan F. Vázquez-CostaJuan F. Vázquez-Costa
Juan F. Vázquez-Costa
NMNuria Muelas
Nuria Muelas
VLVincenzo Lupo
Vincenzo Lupo

7 July 2015 in Brain
Verified
Journal Article
Open access
PDF file
OIOriol Dols Icardo
Oriol Dols Icardo
INIrene Nebot
Irene Nebot
AGAna Gorostidi
Ana Gorostidi
SOSara Ortega-Cubero
Sara Ortega-Cubero
IHIsabel Hernández
Isabel Hernández
O(on behalf of the Dementia Genetics Spanish Consortium (DEGESCO)
on behalf of the Dementia Genetics Spanish Consortium (DEGESCO)

25 October 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
MMMiguel Mazón
Miguel Mazón
Juan F. Vázquez-CostaJuan F. Vázquez-Costa
Juan F. Vázquez-Costa
ATAmadeo Ten-Esteve
Amadeo Ten-Esteve
Luis Martí-BonmatíLuis Martí-Bonmatí
Luis Martí-Bonmatí
The term amyotrophic lateral sclerosis (ALS) comprises a heterogeneous group of fatal neurodegenerative disorders of largely unknown etiology characterized by the upper motor neurons (UMN) and/or lower motor neurons (LMN) degeneration. The development of brain imaging biomarkers is essential to advance in the diagnosis, stratification and monitoring of ALS, both in the clinical practice and clinical trials. In this review, the characteristics of an optimal imaging biomarker and common pitfalls in biomarkers evaluation will be discussed. Moreover, the development and application of the most promising brain magnetic resonance (MR) imaging biomarkers will be reviewed. Finally, the integration of both qualitative and quantitative multimodal brain MR biomarkers in a structured report will be proposed as a support tool for ALS diagnosis and stratification.

18 September 2020 in Journal of Neuromuscular Diseases
Verified
Journal Article
Closed access
PDF file
VSV.A. Sansone
V.A. Sansone
MWM.C. Walter
M.C. Walter
SAS. Attarian
S. Attarian
SDS. Delstanche
S. Delstanche
EME. Mercuri
E. Mercuri
THT. Hagenacker
T. Hagenacker
Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease which affects 1 in 6,000–10,000 live births, caused by loss of the survival motor neuron 1 gene (SMN1). A major focus of therapeutic developments has been on increasing the full-length SMN protein by increasing the inclusion of exon 7 in SMN2 transcripts, enhancing SMN2 gene expression, stabilizing the SMN protein or replacing the SMN1 gene. In June 2017, FDA and EMA have approved the antisense oligonucleotide Nusinersen as the first treatment for all SMA subtypes without age restriction. While prominent treatment effects have been observed in the earlier stages of the disease and in patients up to 15 years of age, there is only limited data from clinical trials in adult SMA patients. First real-world data from neuromuscular clinical centers suggest a therapeutic benefit of nusinersen with a favourable safety profile also in adult SMA patients: in several cases, relevant improvements of motor function is achieved, which might lead to enhanced autonomy in daily life activities and improved quality of life. Systematic follow-up of the motor status with validated instruments is crucial for an adequate monitoring of the therapeutic effects but most of the widely used scales and scores have been developed and evaluated for the pediatric population only. International neuromuscular experts have met in Frankfurt/Main, Germany in May 2019 to discuss relevant aspects of the diagnostic pathway and patient management in adult SMA. The recommendations and challenges in this patient population are discussed.